3,423 trials (keyword fallback)
Breast Cancer · Ovarian Insufficiency · Ovarian Failure
Primary: Number of Participant Ovarian Insufficiency (Without of Menses for 12 Months) After Breast Cancer Diagnosis — 27; 11 Participants
Ovarian Cancer
Primary: Objective Tumor Response — 12.5; 12.1 percentage of participants
Advanced Ovarian Cancer · Primary Peritoneal Cancer · Advanced Breast Cancer
Primary: Percent of Participants Who Achieve a Sustained Progressive Disease (PD) Response, Defined to be at Least 4% Nuclear Area Positive (NAP) γH2AX at the Day 8 Biopsy — 44.4…
Ovarian Cancer · Primary Peritoneal Cancer · Serous Carcinoma Cancer
Primary: Percentage of Participants With an Overall Response Rate — 9.5; 5.6; 0; 11.8 percentage of participants
Retinal Disease
Primary: Change in Best-corrected Visual Acuity (BCVA) in the Study Eye at Two Years Compared to Baseline — 0 ETDRS letters
Systemic Sclerosis · Pulmonary Hypertension
Primary: Mean Pulmonary Arterial Pressure Change From Baseline — -1.0; -0.73 mmHg
Infertility
Primary: Oocytes — 19; 47 oocytes
Infertility
Primary: Total Number of Oocytes — 12.4; 12.1 Number of oocytes
Ovarian Neoplasms
Primary: Purchase Behaviours (Purchase of Items) — 3.2; 2.0; 5.9; 4.3 number of items purchased — p=<0.001
Ovarian Neoplasms · Fallopian Tube Neoplasms · Primary Peritoneal Neoplasms
Primary: 6 Month Progression Free Survival — 0 Participants
Ovarian Tumor · Ovarian Cancer
Primary: Tumor Marker CA125 — 189; 4 U/mL — p=<0.001
High-grade Serous Ovarian Cancer
Primary: Overall Response Rate (ORR) — 1; 0; 0; 0 Participants
Platinum Sensitive Recurrent High-grade Serous Ovarian Cancer With Mutated p53
Primary: Phase Ib: Dose-limiting Toxicities (DLT) (See Description) of Combined APR-246 and Carboplatin/PLD Regimen — 0; 1; 0 Participants
Central Serous Chorioretinopathy
Primary: Multifocal Electroretinogram Amplitudes — 28.4; 32.2; 29.7; 36.1 microvolts
Retinal Disease
Primary: Change in Visual Acuity at Month 3 Compared to Baseline. — 0 ETDRS letters